Chow LQM. Head and neck cancer. N Engl J Med. 2020;382:60–72. https://doi.org/10.1056/NEJMra1715715.

Article  PubMed  CAS  Google Scholar 

Aupérin A. Epidemiology of head and neck cancers: an update. Curr Opin Oncol. 2020;32:178–86. https://doi.org/10.1097/CCO.0000000000000629.

Article  PubMed  Google Scholar 

Szturz P, Vermorken JB. Management of recurrent and metastatic oral cavity cancer: raising the bar a step higher. Oral Oncol. 2020;101: 104492. https://doi.org/10.1016/j.oraloncology.2019.104492.

Article  PubMed  CAS  Google Scholar 

Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7.

Article  PubMed  CAS  Google Scholar 

Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and Neck. N Engl J Med. 2016;375:1856–67. https://doi.org/10.1056/NEJMoa1602252.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gavrielatou N, Doumas S, Economopoulou P, et al. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020;84: 101977. https://doi.org/10.1016/j.ctrv.2020.101977.

Article  PubMed  CAS  Google Scholar 

Ma SJ, Yu H, Khan M, et al. Evaluation of optimal threshold of neutrophil-lymphocyte ratio and its association with survival outcomes among patients with head and neck cancer. JAMA Netw Open. 2022;5: e227567. https://doi.org/10.1001/jamanetworkopen.2022.7567.

Article  PubMed  PubMed Central  Google Scholar 

Kumarasamy C, Tiwary V, Sunil K, et al. Prognostic utility of platelet-lymphocyte ratio, neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in head and neck cancers: a detailed PRISMA compliant systematic review and meta-analysis. Cancers (Basel). 2021;13:4166. https://doi.org/10.3390/cancers13164166.

Article  PubMed  CAS  Google Scholar 

Ma X, Ding Y, Qian J, et al. Nomogram based on monocyte-to-lymphocyte ratio to predict survival of unresectable esophageal squamous cell carcinoma who receive first-line PD-1/PD-L1 inhibitors combined with chemotherapy. Curr Oncol. 2022;29:8937–54. https://doi.org/10.3390/curroncol29110702.

Article  PubMed  PubMed Central  Google Scholar 

Terazawa K, Ohashi T, Shibata H, et al. Immune-modified Glasgow prognostic score: a new prognostic marker for head and neck cancer. Head Neck. 2022;44:2555–63. https://doi.org/10.1002/hed.27170.

Article  PubMed  Google Scholar 

Wang YT, Kuo LT, Weng HH, et al. Systemic immune-inflammation index as a predictor for head and neck cancer prognosis: a meta-analysis. Front Oncol. 2022;12: 899518. https://doi.org/10.3389/fonc.2022.899518.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yang XC, Liu H, Liu DC, et al. Prognostic value of pan-immune-inflammation value in colorectal cancer patients: a systematic review and meta-analysis. Front Oncol. 2022;12:1036890. https://doi.org/10.3389/fonc.2022.1036890.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Guven DC, Erul E, Yilmaz F, et al. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2023;280(5):2471–8. https://doi.org/10.1007/s00405-022-07804-x.

Article  PubMed  Google Scholar 

Yeh CC, Kao HK, Huang Y, et al. Discovering the clinical and prognostic role of pan-immune-inflammation values on oral cavity squamous cell carcinoma. Cancers (Basel). 2023;15:322. https://doi.org/10.3390/cancers15010322.

Article  PubMed  Google Scholar 

Sahin AA, Gilligan TD, Caudell JJ. Challenges With the 8th Edition of the AJCC cancer staging manual for breast, testicular, and head and neck cancers. J Natl Compr Canc Netw. 2019;1:560–4.

Google Scholar 

Fucà G, Guarini V, Antoniotti C, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer. 2020;123:403–9.

Article  PubMed  PubMed Central  Google Scholar 

Corti F, Lonardi S, Intini R, et al. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021;150:155–67. https://doi.org/10.1016/j.ejca.2021.03.043.

Article  PubMed  CAS  Google Scholar 

Şahin AB, Cubukcu E, Ocak B, et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci Rep. 2021;11:14662. https://doi.org/10.1038/s41598-021-94184-7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen X, Hong X, Chen G, et al. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor. Transl Oncol. 2021;17: 101338. https://doi.org/10.1016/j.tranon.2021.101338.

Article  CAS  Google Scholar 

Fucà G, Beninato T, Bini M, et al. The Pan-Immune-Inflammation Value in Patients with metastatic melanoma receiving first-line therapy. Target Oncol. 2021;16:529–36. https://doi.org/10.1007/s11523-021-00819-0.

Article  PubMed  Google Scholar 

Yazgan SC, Yekedüz E, Utkan G, et al. Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors. Prostate. 2022;82:1456–61. https://doi.org/10.1002/pros.24419.

Article  PubMed  CAS  Google Scholar 

Topkan E, Selek U, Kucuk A, et al. Low pre-chemoradiotherapy Pan-Immune-Inflammation Value (PIV) measures predict better survival outcomes in locally advanced pancreatic adenocarcinomas. J Inflamm Res. 2022;18:5413–23. https://doi.org/10.2147/JIR.S385328.

Article  Google Scholar 

Wang SB, Chen JY, Xu C, et al. Evaluation of systemic inflammatory and nutritional indexes in locally advanced gastric cancer treated with adjuvant chemoradiotherapy after D2 dissection. Front Oncol. 2022;12:1040495. https://doi.org/10.3389/fonc.2022.1040495.

Article  PubMed  PubMed Central  Google Scholar 

Guven DC, Sahin TK, Erul E, et al. The association between the Pan-Immune-Inflammation Value and cancer prognosis: a systematic review and meta-analysis. Cancers. 2022;14:2675. https://doi.org/10.3390/cancers14112675.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kayar R, Bastug Y, Tokuc E, et al. Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer. Int Urol Nephrol. 2023. https://doi.org/10.1007/s11255-023-03812-w.

Article  PubMed  Google Scholar 

Provenzano L, Lobefaro R, Ligorio F, et al. The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis. Ther Adv Med Oncol. 2023;15:17588359231165978. https://doi.org/10.1177/17588359231165978.

Article  PubMed  PubMed Central  Google Scholar 

Kucuk A, Topkan E, Ozkan EE, et al. A high pan-immune-inflammation value before chemoradiotherapy indicates poor outcomes in patients with small-cell lung cancer. Int J Immunopathol Pharmacol. 2023;37:3946320231187759. https://doi.org/10.1177/03946320231187759.

Article  PubMed  Google Scholar 

Zhao H, Chen X, Zhang W, et al. Pan-immune-inflammation value is associated with the clinical stage of colorectal cancer. Front Surg. 2022;9: 996844. https://doi.org/10.3389/fsurg.2022.996844.

Article  PubMed  PubMed Central  Google Scholar 

Barker T, Fulde G, Moulton B, et al. An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer. Sci Rep. 2020;10:7355.

Article  Google Scholar 

Ligorio F, Fucà G, Zattarin E, et al. The Pan-Immune-Inflammation-Value predicts the survival of patients with human epidermal growth factor receptor 2 (HER2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers. 2021;13:1964.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Roxburgh CS, McMillan DC. Cancer and systemic inflammation: Treat the tumour and treat the host. Br J Cancer. 2014;110:1409–12. https://doi.org/10.1038/bjc.2014.90.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cook J, Hagemann T. Tumour-associated macrophages and cancer. Curr Opin Pharmacol. 2013;4:595–901. https://doi.org/10.1016/j.coph.2013.05.017.

Article  CAS  Google Scholar 

Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123–34. https://doi.org/10.1038/nrc3004.

Article  PubMed  PubMed Central  CAS  Google Scholar